BioWorld

Aug. 14, 2002

Dendreon's Trp-p8 Gene Platform Garners $110M Genentech Deal

Dendreon Corp. could gain more than $110 million in a deal with Genentech Inc. to develop monoclonal antibodies, small molecules and other products from Dendreon's preclinical Trp-p8 gene platform. (BioWorld Today) Read More

Nobex Raises Two Year's Cash Through $35M Private Placement

GenVec's Flagship AntiCancer Drug, TNFerade, Performs Well In Both Preclinical, Clinical Trials

$37M Addition Brings Archemix Series A Financing To $51.75M

Other News To Note

CollaGenex Testing Periostat In Phase III Against Rosacea

Today's news in brief

BioWorld

BioWorld briefs for July 15, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Illustration of T cells attacking cancer

GABA signaling linked to immune resistance in some tumors

BioWorld

Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...